XERS
Xeris Biopharma Holdings, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
8.33
close · 2026-08-13
value
12
cheaper than peers12
quality
32
stronger fundamentals32
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
34 peerswide variation
Value inputs
| measure | company | vs peers |
| EV to EBITDA | 33.08× | 29 |
| price to sales | 4.34× | 27 |
| forward P/E | 21.36× | 24 |
| price to book | 101.59× | 5 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 28.7% | 83 |
| operating margin | 5.6% | 40 |
| debt to equity | 1987.2% | 5 |
3 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | $52.5M |
| employees | 435 |
| first trade | 2018-06-21 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-10 |